Compare ANIX & CMTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIX | CMTL |
|---|---|---|
| Founded | 1982 | 1967 |
| Country | United States | United States |
| Employees | N/A | 1385 |
| Industry | Biotechnology: Pharmaceutical Preparations | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.6M | 109.7M |
| IPO Year | 2013 | 2024 |
| Metric | ANIX | CMTL |
|---|---|---|
| Price | $2.97 | $3.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $8.67 | $6.00 |
| AVG Volume (30 Days) | 113.0K | ★ 174.9K |
| Earning Date | 05-27-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.82 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $210,000.00 | ★ $499,528,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.56 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.44 | $1.71 |
| 52 Week High | $5.46 | $6.21 |
| Indicator | ANIX | CMTL |
|---|---|---|
| Relative Strength Index (RSI) | 51.78 | 52.30 |
| Support Level | $2.74 | $2.78 |
| Resistance Level | $3.11 | $4.24 |
| Average True Range (ATR) | 0.18 | 0.22 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 36.88 | 62.82 |
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
Comtech Telecommunications Corp is a provider of communications technology and solutions. It operates in two reportable business segments: Satellite and Space Communications and Allerium. The company's Satellite and Space Communications segment, which generates maximum revenue, is organized into four technology areas: satellite modem and amplifier technologies, troposcatter technologies, cybersecurity training, and space components. This segment designs and manufactures modems, amplifiers, traveling wave tube amplifiers, frequency converters, and offers other associated software and services. The Allerium segment provides next-generation 911 (NG-911) infrastructure and solutions for state and local governments and carriers. Geographically, the company derives its key revenue from the USA.